Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)
Mirum doubles down on diversified rare disease strategy [Yahoo! Finance]
Is Mirum Pharmaceuticals on a Strong Path to Profitability? [Yahoo! Finance]
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Morgan Stanley from $95.00 to $123.00. They now have an "overweight" rating on the stock.